flaura trial: impact of os data in advanced nsclc
Published 4 years ago • 645 plays • Length 7:00Download video MP4
Download video MP3
Similar videos
-
4:22
advanced-stage nsclc: overall survival data from flaura
-
2:46
significance of flaura in egfr nsclc
-
2:06
final overall survival (os) data from flaura trial
-
1:59
the flaura trial in egfr nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
12:52
tagrisso mechanism of action
-
3:01
going from stage iv lung cancer to clean scans
-
34:23
management of non-small cell lung cancer (nsclc) with an egfr mutation — karen reckamp, md, ms
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
5:42
osimertinib and the flaura trial
-
0:57
examining the impact of the flaura trial in egfr-mutant nsclc
-
1:16
dr. gandara discusses clinical implications of the flaura study in nsclc
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
2:09
dr. hassan on flaura trial results in egfr-mutant nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
1:29
dr. bertino on the impact of the egfr-mutated subset analysis of impower150 in nsclc
-
6:06
osimertinib, the standard for egfr nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
1:39
dr. sequist on implications of the impower150 trial in advanced nonsquamous nsclc
-
1:55
dr. bauml discusses the flaura study in nsclc